NCT03705429 is a Phase 3 clinical trial of TC-H x Paclitaxel (P) + Trastuzumab(T) in Breast Neoplasms, sponsored by London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's.

What drugs are being tested in NCT03705429?

Interventions in NCT03705429: TC-H x Paclitaxel (P) + Trastuzumab(T).

What condition does NCT03705429 study?

NCT03705429 studies Breast Neoplasms.

Is NCT03705429 still recruiting?

NCT03705429 is currently completed. Last updated 19 August 2022.

Last reviewed 2022-08-19 · How we verify

NCT03705429

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study Comparing Two Standard of Care Adjuvant Chemotherapy Regimens for Lower Risk HER-2 Positive Breast Cancer

Completed Phase 3 Last updated 19 August 2022

What this trial tests

Phase 3 trial testing TC-H x Paclitaxel (P) + Trastuzumab(T) in Breast Neoplasms in 51 participants. Completed in 11 May 2022.

Timeline

1 May 2019

Primary endpoint
11 May 2022

11 May 2022

Quick facts

Lead sponsor	London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Phase	Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	other
Enrollment	51
Start date	1 May 2019
Primary completion	11 May 2022
Estimated completion	11 May 2022
Sites	3 locations across Canada

Drugs / interventions tested

TC-H x Paclitaxel (P) + Trastuzumab(T) — full drug profile →

Conditions studied

Breast Neoplasms — all drugs for Breast Neoplasms →

Sponsor

London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

Who can join

18 and older, any sex, with Breast Neoplasms. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Multi-center, open-label, randomized trial of patients with low-risk, HER2+ disease, who will receive adjuvant taxane-based chemotherapy (i.e. docetaxel and cyclophosphamide with trastuzumab \[TC-H\] or weekly paclitaxel with trastuzumab \[P-H\]) at the standard approved doses, aiming to gather more information regarding cost-effectiveness, toxicity, quality of life (QoL), patient reported outcomes and clinical benefits of the two treatment strategies.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Evolving Role of Risk Tailored Therapy in Early Stage HER2-Positive Breast Cancer: A Canadian Perspective.
McGee SF, Clemons M, Savard MF. · · 2022 · cited 2× · PMID 35735438 · DOI 10.3390/curroncol29060329
The Rethinking Clinical Trials (REaCT) Program: A Pragmatic Research Strategy to Improve Cancer Care for Patients, Caregivers, and Healthcare Systems.
Savard MF, Clemons M, McGee SF. · · 2025 · cited 1× · PMID 41002554 · DOI 10.3390/curroncol32090484

Verify or expand the search:

Other recruiting trials for Breast Neoplasms

Currently open trials in the same condition.

NCT07214532 — Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer · NA · recruiting
NCT07500428 — Construction of a Benchmark for Breast Ultrasound AI Interpretation and Performance Evaluation of Multimodal AI Models · recruiting
NCT07581834 — Efficacy and Safety of Dalpiciclib Combined With Endocrine Adjuvant Therapy for Early HR +/HER2- Breast Cancer: a Multic · Phase 2 · recruiting
NCT07222215 — PhII Randomized CAPecitabine + ELAcestrant vs. Capecitabine Alone in ER+ Breast Cancer (CAPELA) · Phase 2 · recruiting
NCT07465393 — Facility-Based Multi-Modal Rehab vs. Home-Based Resistance Exercise for Quality of Life in Breast Cancer Survivors · NA · recruiting

Other London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's trials

Trials by the same sponsor.

NCT07588711 — Transcutaneous Auricular Vagus Nerve Stimulation as a Treatment for Neuropathic Pain Following Spinal Cord Injury · NA · not yet recruiting
NCT07585292 — Transcutaneous Auricular Vagus Nerve Stimulation as a Treatment for Musculoskeletal Pain in Cerebral Palsy · NA · not yet recruiting
NCT07510906 — Evaluation of a Prostate-Targeted PET Imaging System (P-PET) for Detecting Prostate Cancer · NA · not yet recruiting
NCT03166072 — Health Education vs Meditation in Irreversible Age-Related Vision Loss Patients and Their Caregivers · NA · not yet recruiting
NCT06035809 — Sensory Motor Arousal Regulation Treatment (SMART) Study · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03705429 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Last refreshed: 19 August 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03705429.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing